The goal should be improved metabolic function, better body composition, and a lower-risk physiologic state
Stephen and Dee Down a combined 56lbs
All of these steps may reduce potential side effects and make your switch much smoother
This is because the pathological interactions between sarcopenia and obesity are often overlooked when they are treated separately, and individuals affected by both conditions are at higher risk of developing metabolic dysfunction.[10] To mitigate the loss of skeletal muscle mass and function associated with sarcopenia, various therapeutic targets are being investigated, including activation of sphingosine-1-phosphate, AMPK, and glutathione, as well as inhibition of myostatin (MSTN) and nuclear factor-, with MSTN emerging as a particularly promising target
Reduced potency can make the medication less effective at managing your condition
Chronic immune activation from HIV alters how the body stores fat